---
title: "BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278544718.md"
description: "BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline"
datetime: "2026-03-10T11:17:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278544718.md)
  - [en](https://longbridge.com/en/news/278544718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278544718.md)
---

# BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline

BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/288163328.md)
- [Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer](https://longbridge.com/en/news/288162016.md)
- [Sobi to present new data on pegcetacoplan at ERA 2026](https://longbridge.com/en/news/288238139.md)
- [Bristol Myers Squibb Says Phase 3 Successor-2 Trial Shows MeziKd Achieves 18-Month Median PFS](https://longbridge.com/en/news/288067720.md)
- [Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate](https://longbridge.com/en/news/288144632.md)